New combo therapy aims to boost immune attack on hard-to-treat cancers

NCT ID NCT03589339

Ongoing Disease control Sponsor: Nanobiotix Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with various solid tumors that have spread. The main goal is to find a safe dose and check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer head and neck squamous cell carcinoma hepatocellular carcinoma melanoma metastatic malignant neoplasm metastatic melanoma Mouth Neoplasms non-small cell lung carcinoma oropharynx cancer renal cell carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma urinary bladder cancer urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY METASTASIS FROM MALIGNANT MELANOMA OF SKIN (DISORDER) METASTASIS FROM MALIGNANT TUMOR OF BLADDER (DISORDER) METASTASIS FROM MALIGNANT TUMOR OF CERVIX METASTASIS FROM MALIGNANT TUMOR OF LIVER METASTATIC NSCLC METASTATIC RENAL CELL CARCINOMA METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA MICROSATELLITE INSTABILITY-HIGH SOLID MALIGNANT TUMOUR RADIOTHERAPY SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Locations

Christus St. Vincent Regional Cancer Center

Santa Fe, New Mexico, 87505, United States
Emory University

Atlanta, Georgia, 30308, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21287, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Northwell Health

Manhasset, New York, 11030, United States
Sanford Cancer Center

Sioux Falls, South Dakota, 57104, United States
St Luke's University Health Network

Bethlehem, Pennsylvania, 18015, United States
University of California San Francisco

San Francisco, California, 94158, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of North Carolina, School of Medicine

Chapel Hill, North Carolina, 27516, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.